Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage oncology-focused biotechnology company, announced the establishment of an at-the-market (ATM) offering program under which the Company may offer and sell up to $100.0 million of its securities from time to time, pursuant to a shelf registration statement on Form F-3.
The ATM program allows the Company to issue American Depositary Shares (“ADSs”), each representing ordinary shares, at prevailing market prices or through negotiated transactions, providing flexibility to access capital opportunistically based on market conditions.
Net proceeds from any sales under the ATM program are expected to be used to support the advancement of the Company’s clinical development pipeline, as well as for working capital and general corporate purposes.
Lucosky Brookman LLP served as legal counsel to Kazia Therapeutics Limited in connection with the ATM program. Leerink Partners acted as the sole sales agent.
